Aktuelle Studien bei Erkrankungen der Prostata
Sie befinden sich hier:
Kastrationsresistentes Prostatakarzinom
Studientitel | Status | Seit | Medikation |
MK-3475-641 A Phase III, randomized, double-blind Trial of Pembrolizumab (MK-3475) plus Enzalutamid vs Placebo plus Enzalutamid in Patients with metastatic Castration-Resistant Prostate Cancer | Aktiv | 09.03.2020 | |
MK-3475-921 A Phase III, Randomized, Double-blind Study of Pembrolizumab (MK-3475) plus Docetaxel vs. Placebo plus Docetaxel in Patients with Metastatic Castration resistant Prostate Cancer (mCRPC) | Aktiv | 05.02.2020 | |
MK-7339-010 A Randomized, Open-Label, Phase 3 Trial of Pembrolizumab (MK-3475) in Combination with Olaparib vs Alternative Next-Generation Hormonal Therapy (NHT) in Unselected Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Progressing after NHT and Chemotherapy | Aktiv | 19.12.2019 | |
Clovis – TRITON 3 CO-338-063 A Multicenter, Randomized, Open label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration resistant Prostate Cancer Associated with Homologous Recombination Deficiency | Aktiv | 01.08.2018 | Rucaparib |
Klinische Studie zur Wirksamkeit von intermittierendem Fasten als ergänzende Behandlung unter Chemotherapie des fortgeschrittenen metastasierten Prostatakarzinoms | Aktiv | 29.1.2016 | Docetaxel +/- intermittierendes Fasten |
Ferumoxtran-10 Eine konfirmatorische, prospektive, offene, einarmige, Auswerter-verblindete, multizentrische Phase-3-Studie zur Beurteilung der diagnostischen Genauigkeit der mit Ferumoxtran-10-verstärkten Magnetresonanztomographie (MRT) und des unverstärkten MRTs in Bezug auf die Histopathologie bei neu diagnostizierten Patienten mit Prostatakrebs (PCA), die für die radikale Prostatektomie (RP) mit erweiterter Beckenlymphknotensektion (ePLND) geplant sind | Aktiv | ||
Clovis – TRITON 2 CO-338-052 A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency | Aktiv | Rekrutierung abgeschlossen | Rucaparib |
BAY 17777 ARASENS A Randomized, Double-Blind, Placebo Controlled Phase III Study of ODM-201 versus placebo in combination with standard therapy (Androgen deprivation therapy (ADT) with or without a docetaxel containing chemotherapy regimen) for patients with Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer (mCSPC) | Aktiv | Rekrutierung abgeschlossen | ODM-201 vs placebo in combination + standard therapy with or without a docetaxel |
SOTIO A Randomized, Double-Blind, Multicenter, Parallel-Group, Phase III Study to evaluate Efficacy and Safety of DCVAC/PCa versus Placebo in Men with metastatic Castration resistant Prostate Cancer Eligible for 1st line Chemotherapy | Aktiv | Rekrutierung abgeschlossen | DCVAC Docetaxel |
MDV3100 - 14 Prosper A Multinational; Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer | Aktiv | Rekrutierung abgeschlossen | Enzalutamid |
56021927 PCR3001 Eine randomisierte, placebokontrollierte, doppelblinde Phase-III-Studie zu JNJ-56021927 in Kombination mit Abirateronacetat und Prednison im Vergleich zu Abirateronacetat und Prednison bei Patienten mit chemotherapienaivem metastasiertem kastrationsresistentem Prostatakarzinom | Aktiv | Rekrutierung abgeschlossen | JNJ-56021927 mit Abirateronacetat und Prednison / Abirateronacetat und Prednison |
64091742PCR3001 A phase 3 randomized, placebo-controlled double-blind study of Niraparib in combination with Abiraterone Acetate and Prednisone versus Abiraterone Acetate and Prednisone for first-line treatment of subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC) and DNA-Repair defects | In Planung | ||
MK-3475-991 Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC | In Planung | ||
Exelixis CONTACT-02_XL184-315 A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL 184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy(NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer | In Planung | ||
Ansprechpartner | |||
OÄ Dr. U. Steiner, A. Biniszkiewicz, Tel.: 030-450 615092, Fax: 030-450 7515927 |
Prostatakarzinom
Studientitel | Status | Seit | Medikation |
DKFZ - PSMA - An open-label, single-arm, rater-blinded,mukticenter phase I/II Study to assess safety and diagnostic accurancy and radiotherapeutic implications of pre-operative Ga-68-PSMA-11 PET/CT imaging in comparison to histopathology, in newly-diagnosed prostate cancer (PCA) patients at high risk for metastasis, scheduled for radical prostatectomy (RP) with extended pelvic lymph node dissection (EPLND) | In Planung | pre-operativ PSMA Pet Scan | |
Ansprechpartner | |||
OÄ Dr. U. Steiner, A. Biniszkiewicz, Tel.: 030-450 615092, Fax: 030-450 7515927 |